Dey, Souvik
Sutanto-Ward, Erika
Kopp, Katharina L
DuHadaway, James
Mondal, Arpita
Ghaban, Dema
Lecoq, Inés
Zocca, Mai-Britt
Merlo, Lauren M F
Mandik-Nayak, Laura
Andersen, Mads Hald
Pedersen, Ayako Wakatsuki
Muller, Alexander J http://orcid.org/0000-0001-7854-6933
Clinical trials referenced in this document:
Documents that mention this clinical trial
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
https://doi.org/10.1136/jitc-2020-000605
Documents that mention this clinical trial
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
https://doi.org/10.1136/jitc-2020-000605
Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
https://doi.org/10.1136/jitc-2021-002616
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
https://doi.org/10.1136/jitc-2023-006755
Documents that mention this clinical trial
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
https://doi.org/10.1136/jitc-2020-000605
Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
https://doi.org/10.1136/jitc-2021-002616
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
https://doi.org/10.1136/jitc-2023-006755
Documents that mention this clinical trial
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
https://doi.org/10.1136/jitc-2020-000605
Documents that mention this clinical trial
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
https://doi.org/10.1136/jitc-2020-000605
Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4<sup>+</sup>and CD8<sup>+</sup>T cells for immunotherapy of cancer
https://doi.org/10.1136/jitc-2022-004709
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
https://doi.org/10.1136/jitc-2023-006847
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
https://doi.org/10.1136/jitc-2023-006755
Funding for this research was provided by:
IO Biotech ApS (Sponsored research agreement)